Is BMY or JNJ more undervalued in 2026?

CirclFi compares Bristol-Myers Squibb Company (BMY) and Johnson & Johnson (JNJ) using 13 institutional-grade valuation models. BMY has a Quality of Company score of 10.0/10 while JNJ scores 9.7/10.

Which is a better buy — BMY or JNJ?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BMY and JNJ valuations compare?

BMY at $56.91 and JNJ at $230.80 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BMY vs JNJ Valuation Comparison 2026 — Intrinsic Value Analysis

BMY

Drug Manufacturers - General

Bristol-Myers Squibb Company

Quality

10.0

out of 10

Value Trap

SAFE

Price

$56.91

Last close

Models

12/13

Active

JNJ

Drug Manufacturers - General

Johnson & Johnson

Quality

9.7

out of 10

Value Trap

SAFE

Price

$230.80

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	BMY Fair Value	BMY Upside	JNJ Fair Value	JNJ Upside
Bayesian DCF	Intrinsic	$123.15	+116.4%	$76.94	-66.7%
Earnings Power Value	Intrinsic	$52.56	-7.6%	$50.60	-78.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BMY vs JNJ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BMY vs JNJ — Which Stock Is More Undervalued?

BMY scores higher with a 10.0/10 quality rating vs JNJ's 9.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bristol-Myers Squibb Company (BMY) and Johnson & Johnson (JNJ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BMY currently trades at $56.91 with a QOC of 10.0/10, while JNJ trades at $230.80 with a QOC of 9.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).